 |  |  |
|---|
POVIDIEN
COMBATING COV19
ABOUT POVIDIEN
Our Background
Povidien was set up as a direct response to the Covid 19 crisis by a pharmacist and two pharma industry veterans hoping to make a meaningful contribution to an already under pressure and under resourced Health Service.
POVIDIEN GOALS
Protection when it matters
Research novel solutions that will aid those on the frontline
Produce a product that aims to potentially stop transmission of SARsCoV2 to the caregiver
POVIDONE IODINE
Used every day already in Hospitals for years
50 years ago NASA used it to prevent "Moon Germs". Every day it is used in hospitals to prevent transmission of microbes as a surgical scrub. During Covid, Povidien reformulated it so it can be used safely in the nose and mouth.
Aug 2020, World Health Organisation recommends PVPI pre-procedure and pre-examination to reduce SARs CoV2 viral load... Why?
WHO CAN BENEFIT?
DENTISTS & ORTHODONTISTS
ENT, H&N, MAXFAX & ENDOSCOPY
ANAESTHETISTS & ICU
OUR PRODUCT
The high exposure risk of frontline healthcare workers to the virus was immediately identified as an obvious pressure point within the system, and we actively researched pharmaceutical medicines that could potentially reduce the transmission risk.
Following an intensive review of the research, Povidone Iodine was identified as a simple medicine with impressive antiviral activity that could be of use.
Initial inquiries from the medical profession revealed that licensed Povidone Iodine mouthwash had not been manufactured or available in Europe for some years, and that there was renewed interest in its harnessing its antiviral potential.
Having identified an unmet demand for the medicine we set about manufacturing a medicine to supply to front line healthcare workers. The first product containing Povidone Iodine was manufactured by Povidien in June (product cannot be named on the website for regulatory reasons). The product is classified as exempt/unlicensed medication, and it is suitable for use in the oral and nasal cavity. The Povidone Iodine molecule has been shown to inactivate the SARS-CoV-2 virus in 15 seconds at a concentration within 0.08% of our product and has established tolerability and is safe for up to 5 months use.
Our vision is that it will be common practice to be administered as a pre-procedural rinse and nasal spray which will inactivate and reduce viral load, thus reducing the risk of transmission of the virus to healthcare staff in the immediate vicinity. We also are exploring the possibility of staff in healthcare settings self-administering the medicine to reduce their risk of contracting the virus. Gargling is common practice in healthcare settings in Japan to reduce respiratory infections.
Povidien is researching other pipeline products with the potential to protect vulnerable populations in society.
SCIENTIFIC EVIDENCE FOR POVIDONE IODINE V SARS COV2
IN VIVO EVIDENCE IN COVID PATIENTS
Lamas et al
Greater than a 5 log 10 reduction in viral load demonstrated in vivo in saliva samples.
“the application of PVP-I for the general population could be considered as a supplementary prevention measure when a risk scenario is foreseen such as the generation of aerosols”
IN VITRO
Better than Hydrogen Peroxide
"After the 15‐second and 30‐second contact times, PVP‐I oral antiseptic rinse at all 3 concentrations of 0.5%, 1.25% and 1.5% completely inactivated SARS‐CoV‐2. The H2O2 solutions at concentrations of 1.5% and 3.0% showed minimal viricidal activity after 15 seconds and 30 seconds of contact time."
IN VITRO
Frank et al.
"Povidone-iodine nasal antiseptic solutions at concentrations as low as 0.5% rapidly inactivate SARS-CoV-2 at contact times as short as 15 seconds. Intranasal use of PVP-I has demonstrated safety at concentrations of 1.25% and below and may play an adjunctive role in mitigating viral transmission beyond personal protective equipment"
OTHER INTERESTING READING
Published Pre-Covid
2000 to 2019
Yoneyama A, Shimizu M, Tabata M, Yashiro J, Takata T, Hikida M. In vitro short-time killing activity of povidone-iodine (Isodine Gargle) in the presence of oral organic matter. Dermatology 2006; 212(Suppl. 1): 103-8
Reimer K, Wichelhaus TA, Schafer V et al. Antimicrobial effectiveness of povidone-iodine and consequences for new application areas. Dermatology 2002; 204(Suppl 1): 114-20.
Eggers M, Eickmann M, Zorn J. Rapid and effective virucidal activity of povidone-iodine products against Middle East Respiratory Syndrome Coronavirus (MERS-CoV) and Modified Vaccinia Virus Ankara (MVA). Infect Dis Ther. 2015;4:491-501.
Eggers M, Eickmann M, Kowalski K, Zorn J, Reimer K. Povidone-iodine hand wash and hand rub products demonstrated excellent in vitro virucidal efficacy against Ebola virus and modified vaccinia virus Ankara, the new European test virus for enveloped viruses. BMC Infect Dis. 2015;15:375.
Eggers M, Koburger-Janssen T, Eickmann M, Zorn J. In vitro bactericidal and virucidal efficacy of Povidone-Iodine gargle/mouthwash against respiratory and oral tract pathogens. Infect Dis Ther. 2018;7:249-59.
Eggers M. Infectious Disease Management and Control with Povidone Iodine. Infect Dis Ther. 2019;8:581-593.https://doi.org/10.6084/m9.figshare.9168032.
Japan Ministry of Health, Labour and Welfare. Pandemic influenza preparedness action plan of the Japanese Government. 2007. http://www.mhlw.go.jp/english/topics/influenza/dl/pandemic02.pdf. Accessed Mar 2020.
Ripa S, Bruno R, Reder R. Clinical applications of Povidone-Iodine as a topical antimicrobial handbook of topical antimicrobials industrial applications industrial applications in consumer products and pharmaceuticals. Boca Raton:CRC;2002.
Nakagawa Y, Shiraishi T. Evaluation of the bactericidal activity pf povidone-iodine and commercially available gargle preparations Dermatology, 2002;204 (Suppl 1): 37-41.
Ogata Junichi, Minami Kouichiro. Miyamoto Hiroshi, Horishita Takafumi, Ogawa Midori, Sata Takeyoshi, Taniguchi Hatsumi. Gargling with povidone-iodine reduces the transport of bacteria during oral intubation. Can J Anesth. 2004;51(9):932-6.
Nagatake T, Ahmed K, Oishi K. Prevention of respiratory infections by povidone-iodine gargle. Dermatology. 2002;204(suppl1):32-6.
Petersen PE, Bourgeois D, Ogawa H, Estupinan-Day S, Ndiaye C. The global burden of oral diseases and risks to oral health. Bull World Health Organ 2005;83:661-9.
Arakeri G, Brennan PA. Povidone-iodine: an anti-oedematous agent? Int J Oral Maxillofac Surg 2011;40:173-6.
1965 to 2000
Lanker-Klossner B, Widmer HR, Frey F. Non-development of resistance by bacteria during hospital use of povidone-iodine. Dermatology 1997;195: 10-3.
Prince HN, Nonemaker WS, Norgard RC, Prince DL. Drug resistance studies with topical antiseptics. J Pharm Sci 1978; 67:1629-31.
Rikimaru T, Kondo M, Kajimura K et al. Efficacy of common antiseptics against mycobacteria. Int J Tuberc Lung Dis 2000; 4:570-6.
Kawana T, Kitamura T, Nakagomi O et al. Inactivation of human viruses by povidone-iodine in comparison with other antiseptics. Dermatology 1997; 195:29-35.
Boyce ST, Warden GD, Holder IA. Cytotoxicity testing of topical antimicrobial agents on human keratinocytes and fibroblasts for cultured skin grafts. J Burn Care Rehabil. 1995;16:97-103.
Shiraishi T, Nakagawa Y. Evaluation of the bactericidal activity of povidone-iodine and commercially available gargle preparations. Dermatology. 2002;204(suppl 1):37-41.
Domingo NA, Farrales MS, Loya RM, Pura MA, Uy H. The effect of 1% povidone iodine as a pre-procedural mouthrinse in 20 patients with varying degrees of oral hygiene. J Philipp Dent Assoc 1996;48:31-8.